| EX1511 MINIMAL RESIDUAL DISEASE (MRD) MONITORING FOR B-CLL |
| Specimen: |
3 mL (1 mL min.) Bone Marrow (first pull aspirate) in 1 Green Top (Sodium Heparin) tube AND 4 mL (3 mL min.) whole blood in 2 Green Top (Sodium Heparin) tubes. Mix thoroughly & Ship immediately at 18–22°C or 2-8 deg °C. DO NOT FREEZE. |
| Stability: |
| Room |
Refrigerated |
Frozen |
| 72 hrs |
72 hrs |
NA |
|
| Method: |
FLOW CYTOMETRY |
| Comment: |
|
| Report: |
Contact us to know the TAT. |
| Usage: |
This assay helps to assess response to therapy and compares the efficacy of different therapeutic approaches. Detection of minimal residual disease level predicts progression-free survival and overall survival after routine chemotherapy, after immunochemotherapy, and after stem cell transplantation. The eradication of the minimal residual disease in CLL predicts improved outcomes. |
| Doctor Specialty: |
Hematologist, Oncologist |
| Disease: |
Leukemia |
| Components: |
|
| Courier Charges: |
|
| Home Collection: |
Available (*T&C Apply) |
| Department: |
FLOW CYTOMETRY |
| Pre Test Information: |
The following information is mandatory: Sample time point (Chemotherapy time points); Previous diagnostic immunophenotype report; Clinical history and original TRF; Date and time when the sample was drawn to be mentioned on the TRF; Therapy details. |
Reviews
There are no reviews yet.